A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Latest Information Update: 23 Oct 2024
Price :
$35 *
At a glance
- Drugs Pitavastatin (Primary) ; Venetoclax (Primary) ; Azacitidine; Decitabine
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
- 06 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.